4D Molecular Therapeutics (FDMT) Leerink Global Healthcare Conference 2026 summary

Program updates and clinical progress

• Lead asset 4D-150 is in two phase III programs (4FRONT-1 and 4FRONT-2) for Wet AMD and DME, with 4FRONT-1 enrollment completed in 11 months, ahead of projections despite upsizing the trial.

• Enrollment pace reflects high unmet need and strong physician and patient enthusiasm, supported by survey data showing gene therapy as the most exciting development among retina specialists.

• Phase I/II PRISM study showed robust efficacy across severe, broad, and newly diagnosed patient populations, with up to 90% treatment burden reduction and 70% injection-free rates in recent diagnoses.

• Phase III trials focus on recently diagnosed, mostly treatment-naive patients, with 4FRONT-2 including some with prior injections.

• DME trial initiation is planned for Q3 2026, fully funded, with potential for DME to match or exceed AMD in commercial opportunity due to higher prevalence and unmet need.

Commercialization strategy and market dynamics

• U.S. commercialization will leverage a higher price point reflecting multi-year benefit, upfront reimbursement, and practice capacity relief, while Europe will focus on government-controlled pricing and vision preservation value.

• Asia-Pacific commercialization is through a partner model with upfront, cost-sharing, milestones, and royalties; similar partnerships may be considered for Europe post-phase III data.

• Pricing strategy aims to balance U.S. and EU incentives, MFN impacts, and payer value, with significant pricing flexibility due to low cost of goods (<$1,000 per treatment).

• Commercial label is expected to be broad, not restricted by time since diagnosis, enabling treatment of both naive and pretreated patients.

• Medical affairs team is already engaging with retina specialists, with plans to expand market-shaping and education efforts 12 months ahead of potential approval.

Physician and patient engagement

• Physician enthusiasm for gene therapy is high, with 54% of retina specialists citing it as the most exciting development.

• 4D-150 is expected to shift clinical practice from "treat and extend" to "treat and monitor," reducing visit frequency and treatment burden.

• Ongoing education and operational adjustments are planned to support adoption of the new treatment paradigm.